Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer

Lung Cancer

Volumn 34, Issue SUPPL. 4, 2001, Pages 111-115

  Momparler, Richard L ^a   Ayoub, J ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Decitabine; DNA methylation; NSCLC

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; VINDESINE;

ADULT; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DNA METHYLATION; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0035196111     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00397-X     Document Type: Conference Paper

References (43)

1. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer
2. Cisplatin and gemcitabine in non-small-cell lung cancer
3. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non small cell lung carcinoma. A phase II trial
4. A phase II study of gemcitabine plus etoposide in the treatment of patients with advanced non-small cell lung carcinoma
5. Cancer epigenetics comes of age
6. DNA hypermethylation in tumorigenesis. Epigenetics joins genetics
7. DNA methylation and cancer (A review)
8. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16 protein induction by 5-aza-2′-deoxycytidine
9. Inactivation of the CDKN2/p16MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
10. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression
11. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
12. Methylation and silencing of the thrombospondin-1 promoter in human cancer
13. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
14. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G-A mutations in K-ras in colorectal tumorigenesis
15. Cellular differentiation, cytidine analogs and DNA methylation
16. Incorporation of 5-aza-2′-deoxycytidine-5′-triphoshphate into DNA: interactions between DNA polymerase a and DNA methylase
17. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia
18. Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-β-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia
19. Preclinical antitumor activity of 5-aza-2′-deoxycytidine against human head and neck cancer xenografts
20. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia
21. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia
22. The antileukemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia
23. Decitabine studies in chronic and acute myelogenous leukemia
24. 5-aza-2′ deoxycytidine (Decitabine) induces trilineage response in unfavorable myelodysplastic syndromes
25. Phase I and pharmacokinetic study of 5-Aza-2′-deoxycytidine (NSC 127716) in cancer patients
26. 2-Deoxy 5-azacytidine and fetal hemoglobin in sickle cell anemia
27. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer
28. Spontaneous regression of cancer: possible mechanism
29. Tumor-suppressive effect of retinoic acid receptor β in human epidermoid lung cancer cells
30. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development
31. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells
32. Demethylation by 5′-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells
33. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung cancer
34. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns
35. The DNA methylation machinery as a therapeutic target
36. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation
37. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
38. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE)
39. Quantitation of inhibition of DNA methylation of retinoic acid receptor β gene by 5-aza-2′-deoxycytidine in tumor cells using single nucleotide extension assay
40. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
41. Prediciting lung cancer by detecting aberrant promoter methylation in sputum
42. Drug resistance to 5-aza-2′-deoxycytidine, 2,2′-difluorodeoxycytidine and cytosine arabinoside by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells
43. Retroviral transfer and long term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice